

Progress and Status of
5th Mid-term Strategic Plan
'Dramatic Leap Plan'

Haruo Naito
President & CEO
Eisai Co., Ltd.

Contents


New Globalization Era


Japan


**North
America**

Europe

Asia







Integrative Oncology Approach

Cancer Therapies

Cytotoxics
Anti-angiogenesis
Antibodies
Vaccines


Supportive Therapies

Anemia
Thrombosis
Pain
Nausea/vomiting
Oral mucositis
Neuropathy



Status	Research Code	Mechanism of Action	Therapeutic Strategy	Filing Schedule	Development Area
---------------	----------------------	----------------------------	-----------------------------	------------------------	-------------------------

Product



Pipeline

Current Status of Global NME Development (1)

Current Status of Global NME Development (2)

Global NME Projects

Project Code	Target Indication	Progress	Submission Target
--------------	-------------------	----------	-------------------

Development Projects in Japan

Project Code

Progress

Submission
Target

New Indication/Formulation Programs

Product	Target Indication	Submission Target
----------------	--------------------------	------------------------------

Enriching Return to Shareholders

